Trial Profile

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Susoctocog alfa (Primary)
Indications Haemophilia A
Focus Adverse reactions
Sponsors Baxalta

Most Recent Events

16 Jul 2019 Status changed from active, no longer recruiting to completed.
30 Apr 2019 Planned number of patients changed from 40 to 60.
30 Apr 2019 Planned End Date changed from 1 Aug 2019 to 7 Jun 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com